RT Journal Article
SR Electronic
T1 A Multicenter Evaluation of the Impact of Procedural and Pharmacological Interventions on Deep Learning-based Electrocardiographic Markers of Hypertrophic Cardiomyopathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.15.24301011
DO 10.1101/2024.01.15.24301011
A1 Dhingra, Lovedeep S
A1 Sangha, Veer
A1 Aminorroaya, Arya
A1 Bryde, Robyn
A1 Gaballa, Andrew
A1 Ali, Adel H
A1 Mehra, Nandini
A1 Krumholz, Harlan M.
A1 Sen, Sounok
A1 Kramer, Christopher M
A1 Martinez, Matthew W
A1 Desai, Milind Y
A1 Oikonomou, Evangelos K
A1 Khera, Rohan
YR 2024
UL http://medrxiv.org/content/early/2024/01/17/2024.01.15.24301011.abstract
AB Artificial intelligence-enhanced electrocardiography (AI-ECG) interpretation can identify hypertrophic cardiomyopathy (HCM) on 12-lead ECGs and is a novel way to monitor response to treatment. While initial therapies were procedural – i.e. the surgical or percutaneous reduction of the interventricular septum (SRT), medical therapy with mavacamten offers an oral alternative. To evaluate biological response to SRT, we applied an AI-ECG model for HCM detection to ECG images obtained from the same patients before and after SRT across three sites: Yale New Haven Health System (YNHHS), Cleveland Clinic Foundation (CCF), and Atlantic Health System (AHS). We also applied the model in ECGs from patients who had received mavacamten at YNHHS over the past year since its approval. A total of 70 patients underwent SRT at YNHHS, 100 patients at CCF, and 145 at AHS. Among patients at YNHHS, there was no significant change in the AI-ECG score before versus after SRT (pre-SRT: 0.55 [IQR 0.24–0.77] vs post-SRT: 0.59 [IQR 0.40–0.75], p = 0.42 by Wilcoxon signed-rank test). The AI-ECG HCM scores were higher post SRT at CCF (0.61 [IQR 0.32–0.79] vs 0.69 [IQR 0.52–0.79], p = 0.003) and AHS (0.52 [IQR 0.35– 0.69] vs 0.61 [IQR 0.49–0.70], p < 0.001). At YNHHS, among 36 patients undergoing treatment with Mavacamten, the median AI-ECG score prior to starting mavacamten was 0.46 (IQR 0.21–0.72). At the end of a median follow-up period of 237 days (IQR 140–338), the median AI-ECG score decreased significantly to 0.28 (IQR 0.11–0.50, p = 0.002). Our results demonstrate a measurable difference in the myocardial effects of SRT and mavacamten detectable on ECGs, which can reflect different mechanisms for modification of the HCM substrate. Our multicenter design also demonstrates the feasibility of an image-based AI-ECG approach for disease monitoring in HCM at the point-of-care.Competing Interest StatementMr. Sangha and Dr. Khera are the coinventors of U.S. Provisional Patent Application No. 63/346,610, 'Articles and methods for format-independent detection of hidden cardiovascular disease from printed electrocardiographic images using deep learning'. Dr. Khera receives support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775) and the Doris Duke Charitable Foundation (under award 2022060). He receives support from the Blavatnik Foundation through the Blavatnik fund for Innovation at Yale. He also receives research support, through Yale, from Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is an Associate Editor at JAMA. In addition to 63/346,610, Dr. Khera is a coinventor of U.S. Provisional Patent Applications 63/177,117, 63/428,569, and 63/484,426. Dr. Khera and Dr. Oikonomou are co-founders of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care. Dr. Oikonomou is a co-inventor of the U.S. Patent Applications 63/508,315 & 63/177,117 and has served as a consultant to Caristo Diagnostics Ltd (all outside the current work). Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs, was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of Hugo Health, a personal health information platform, and co-founder of Refactor Health, a healthcare AI-augmented data management company. Mr. Sangha, Dr. Krumholz, and Dr. Khera are cofounders of Ensight-AI, Inc., a Yale-backed startup focusing on cardiovascular diagnostics. Dr. Desai acknowledges The Haslam family endowed chair in cardiovascular medicine and receives philanthropic support from the Holekamp and Stinson family.Funding StatementThe study was supported in part by Bristol Myers Squibb (BMS) and the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775 to Dr. Khera, and award 1F32HL170592-01 to Dr. Oikonomou). The SRT patient cohort from YNHHS (Yale New Haven Health System) is part of this analysis. Data from this cohort were presented at the 2023 AHA Scientific sessions. The funders had no role in the design and conduct of the protocol; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Yale institutional review board reviewed the study, approved the study protocol, and waived the need for informed consent, as the study represents a secondary analysis of existing data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe dataset cannot be made publicly available because they are electronic health records. Sharing this data externally without proper consent could compromise patient privacy and would violate the Institutional Review Board’s approval for the study. The code for the study is available from the authors upon request.